📰 Slate Development News
Page 3 - Slate Development News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Slate Development. Real-time updates on events, politics, business and more.
May 31, 2022
AstraZeneca’s Evusheld (tixagevimab and cilgavimab, formerly AZD7442) retains neutralisation activity against the emerging Omicron BA.4 and BA.5 (BA.4/5) variants, says preclinical pseudovirus assay data from the University of Oxford.
March 21, 2022
EVUSHELD™ long-acting antibody combination retains neutralizing activity against Omicron variants including BA.2 in new independent studies - read this article along with other careers information, tips and advice on BioSpace
March 21, 2022
Middle-East Arab News and Opinion - Asharq Al-Awsat is the world’s premier pan-Arab daily newspaper, printed simultaneously each day on four continents in 14 cities
March 21, 2022
This is the first data looking at the impact of AstraZeneca’s Evusheld treatment on “cousins” of the Omicron variant following a recent global spike in cases.
March 21, 2022
(RTTNews) - British drug major AstraZeneca PLC (AZN, AZN.L) Monday said that data from new independent studies showed that EVUSHELD (tixagevimab c...
March 8, 2022
/PRNewswire/ -- BioNJs Twelfth Annual BioPartnering Conference, developed in concert with J.P. Morgan and Johnson & Johnson Innovation, will take place May...
December 11, 2021
Updated results from the MRD cohort of the Phase 2 CAPTIVATE study also highlight potential for treatment-free remissions with IMBRUVICA® plus venetoclax in an oral presentation at ASH... | December 11, 2021
December 1, 2021
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX...
December 1, 2021
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX...
July 14, 2021
Hits: 233 DARZALEX FASPRO® is now the first and only subcutaneous anti-CD38 monoclonal antibody approved in combination with pomalidomide and dexamethasone HORSHAM, PA, USA I July 12, 2021 I The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult patients with multiple myeloma w...